Despite these apparent negative results, we hypothesize that the outcome in the treatment of thrombotic JAK2-V617F-positive MPN would have been different, because of the mutation-inherent overactivation of LFA-1, (CD11a/CD18) [22]. The gene discussed is JAK2; the disease is myeloproliferative disorder.